CD8A and ovarian carcinoma: The Ovarian Tumor Tissue Analysis Consortium [33] has demonstrated a clear dose–response relationship between CD8+ tumor-infiltrating lymphocytes (TILs) and improved survival rates in ovarian cancer patients.